Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.
Saved in:
| Title: | Criteria Clinicians Use to Classify Patients as High Risk in Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. |
|---|---|
| Authors: | Freedland SJ; Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars‑Sinai Medical Center, 8635 West 3rd Street, 1070W, Los Angeles, CA, 90048, USA. Stephen.Freedland@cshs.org.; Durham VA Medical Center, Durham, NC, USA. Stephen.Freedland@cshs.org., Ribbands A; Adelphi Real World, Bollington, Cheshire, UK., Touya M; Astellas Pharma Inc., Northbrook, IL, USA., Butcher J; Adelphi Real World, Bollington, Cheshire, UK., Walley M; Adelphi Real World, Bollington, Cheshire, UK., Russell D; Pfizer Inc., New York, NY, USA., Bland CS; Pfizer Inc., New York, NY, USA., Ivanova JI; Pfizer Inc., New York, NY, USA. |
| Source: | Advances in therapy [Adv Ther] 2026 Jun 24. Date of Electronic Publication: 2026 Jun 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-026-03624-1 |
